Published in Gene Therapy Weekly, May 6th, 2004
In this trial, this drug candidate was safe and biologically active. HYB2055 is a second-generation immunomodulatory oligonucleotide (IMO) that combines a novel DNA structure, referred to as an Immunomer, and a synthetic CpR immunomodulatory motif.
"HYB2055 has exhibited an excellent safety profile over the 32-fold range of dosages evaluated in this phase I trial," said R. Russell Martin, MD, senior vice president of drug development at Hybridon. "Evidence of biological activity by several parameters was seen at all dose levels administered and we have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.